A new study suggests that inpatient statin use is linked to improved outcomes after intracranial hemorrhage. And 2 new studies suggest that a new class of injectable antihyperlipidemics, the PSK9 inhibitors--which have been shown to lower LDL-- may decrease cardiovascular events, including stroke.
Details of those studies appear in the following slides. Take home points include:
- Inpatient statin use is linked to improved outcomes after ICH, and that stopping statins during hospitalization is associated with worse outcomes.
- PSK9 inhibitors are a new class of injectable antihyperlipidemics that have been shown to lower LDL and may also decrease risk of cardiovascular events, including stroke
- A study has suggested that evolocumab, a new PSK9 inhibitor, plus standard therapy reduces LDL by 61% and cardiovascular events by about half, compared to standard therapy alone
- Another study has suggested that alirocumab, also a PSK9 inhibitor, reduces LDL by 62% and cardiovascular risk by about half, compared to placebo
- Both PSK9 inhibitors were linked to increased rates of neurocognitive disorders